What Is Ipamorelin?

Overview

Ipamorelin is a synthetic pentapeptide classified as a growth-hormone-releasing peptide (GHRP). In research models it is valued for its selectivity: it stimulates growth-hormone release through the ghrelin receptor (GHS-R1a) with comparatively little effect on cortisol, prolactin or ACTH. That clean signalling profile is the main reason it appears so often in studies that aim to isolate growth-hormone pulses from confounding hormonal noise.

How Ipamorelin Works

The compound mimics ghrelin at the GHS-R1a receptor on the anterior pituitary, prompting a pulse of growth-hormone secretion. Unlike earlier secretagogues, its narrow receptor activity means it largely avoids the stress-hormone spillover seen with less selective GHRPs. In combination research it is frequently paired with a GHRH analog (such as CJC-1295) to model the synergistic "GHRH + GHRP" growth-hormone axis.

What the Research Explores

• Growth-hormone pulse regulation and the dynamics of pituitary secretion.
• Muscle and connective-tissue regeneration pathways.
• Metabolic function and nutrient partitioning models.
• Ghrelin-receptor-specific signalling mechanisms.

Forms & Handling

Ipamorelin is typically supplied as a lyophilized powder, most commonly in a 5 mg vial. It is reconstituted with bacteriostatic or sterile water for laboratory work and kept refrigerated once in solution. See the dosing protocol below for the reconstitution math expressed in insulin-syringe units.

Safety & Research Notes

Because Ipamorelin is an investigational research compound, there is no approved human or veterinary use and no established safety profile for administration. The literature is confined to laboratory and pre-clinical contexts. Anything described here is mechanistic background, not a usage recommendation.

References

Related Protocols